Anebulo Pharmaceuticals, Inc. (ANEB)

NASDAQ: ANEB · IEX Real-Time Price · USD
3.080
+0.180 (6.21%)
Mar 28, 2024, 3:58 PM EDT - Market closed

Company Description

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction.

The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.

Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals logo
Country United States
Founded 2020
IPO Date May 7, 2021
Industry Biotechnology
Sector Healthcare
Employees 2
CEO Richard Anthony Cunningham

Contact Details

Address:
Jfl Capital Management, 1017 Rr 620 S, Suite 107
Lakeway, Texas 78734
United States
Phone 737 203 5270
Website anebulo.com

Stock Details

Ticker Symbol ANEB
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
IPO Price $7.00
CIK Code 0001815974
CUSIP Number 034569103
ISIN Number US0345691036
Employer ID 85-1170950
SIC Code 2834

Key Executives

Name Position
Dr. Joseph F. Lawler M.D., Ph.D. Founder and Chairman
Dr. Kenneth C. Cundy Ph.D. Chief Scientific Officer
Richard Anthony Cunningham Chief Executive Officer and Director
Daniel V. George Principal Accounting Officer, Acting Chief Financial Officer and Secretary
Scott L. Anderson Head of Investor Relations and Public Affairs

Latest SEC Filings

Date Type Title
Feb 13, 2024 10-Q Quarterly Report
Feb 13, 2024 8-K Current Report
Nov 21, 2023 8-K Current Report
Nov 14, 2023 10-Q Quarterly Report
Nov 14, 2023 8-K Current Report
Oct 30, 2023 ARS Filing
Oct 30, 2023 DEF 14A Other definitive proxy statements
Oct 19, 2023 PRE 14A Other preliminary proxy statements
Oct 6, 2023 8-K Current Report
Sep 29, 2023 8-K Current Report